Incidence and outcome of immune checkpoint-induced pneumonitis in oncology patients with history of pulmonary disease

BackgroundImmune checkpoint-induced pneumonitis (ICIP) is one of the most fatal adverse events caused by immune checkpoint inhibitors (ICI) and accounts for 35% of anti-PD-[L]1-related deaths. Risk factors including thoracic radiation and use of EGFR tyrosine kinase inhibitors have been identified a...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Emily Allen, Godsfavour Umoru, Veronica Ajewole, Eric Bernicker
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	Frontiers Media S.A. 2023-10-01
Σειρά:	Frontiers in Oncology
Θέματα:	immune checkpoint-induced pneumonitis immunotherapy pulmonary disease immune checkpoint inhibitors PD-1/PD-L1 inhibitors
Διαθέσιμο Online:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1283360/full
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!